Brought to you by 
Aileron partners Stapled Peptide platform with Roche; terminated
26 Jun 2017
Executive Summary
Securing its first ever partner, Aileron Therapeutics Inc. (peptide stabilizing technology) has agreed to work with Roche on Stapled Peptide drug candidates against five targets in the Big Pharma's therapeutic areas of interest--cancer, virology, inflammation, metabolic disease, and neurology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aileron partners Stapled Peptide platform with Roche; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice